The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial

We aimed to explore the prognostic value of patient-reported health-related quality of life (HRQoL) data for the achievement of early molecular response (EMR) at 3 months in patients with chronic phase chronic myeloid leukemia (CP-CML). We analyzed HRQoL baseline data of 436 newly diagnosed patients...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Fabio Efficace, Laura Cannella, Isabella Capodanno, Rosaria Sancetta, Veronica Porcu, Monia Lunghi, Annalisa Biagi, Fausto Castagnetti, Giovanni Caocci, Thomas Baldi, Roberto Marasca, Massimiliano Bonifacio, Antonella Gozzini, Bruno Martino, Federica Sora, Peter E. Westerweel, Paola Fazi, Marco Vignetti, Fabrizio Pane, Massimo Breccia
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Subjects:	quality of life patient reported outcome (PRO) functioning chronic myeloid leukemia (CML) early molecular response (EMR)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1645217/full